

<h3>Bibliografía</h3>

    <ol>
        <li>Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion 2012;52(Suppl. 1):20S-29S.</li>
        <li>Hall DP, Lone NI, Watson DM, Stanworth SJ, Walsh TS; for the Intensive Care Study of Coagulopathy (ISOC) Investigators. Factors associated with prophylactic plasma transfusion before vascular catheterization in non-bleeding critically ill adults with prolonged prothrombin time: a case-control study. Br J Anaesth 2012;109:919-27.</li>
        <li>Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006;135:220-7.</li> 
        <li>Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957-65.</li>
        <li>McQuilten ZK, Crighton G, Brunskill S, et al. Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review. Transfus Med Rev 2018;32:6-15.</li>
        <li>Godier A, Greinacher A, Faraoni D, Levy JH, Samama CM. Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:170-4.</li>
        <li>Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016;20:100.</li>
        <li>Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al.; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32.</li>
        <li>Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia 2015;70(Suppl 1):50-3.</li>
        <li>Hunt BJ. Intensive and critical care. In: Key NS, Makris M, Lillicrap D, editors. Practical Haemostasis and Thrombosis. D. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons Inc., 2017. p. 414-32.</li>
        <li>Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007:2007:172-8.</li>
        <li>Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018;22;131:845-54.</li>
        <li>Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.</li>
        <li>Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, López-Rodríguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.</li>
        <li>Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.</li>
        <li>Afshari A, Wetterslev J, Brok J, Møller AM. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008;(3):CD005370.</li>
        <li>Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodríguez AL, et al.; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47.</li>
        <li>Warkentin TE. Hos I diagnose and manage HIT. Hematol Am Soc Hematol Educ Program 2011;2011:143-9.</li>
        <li>Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence based Practical Guidelines. Chest 2012;141:e45S-530S.</li>
        <li>Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Management of massive and nonmassive pulmonary embolism. Arch Med Sci 2012;8:957-69.</li>
        <li>Kearon C, Akl EA, Ornelas J, Blaivas A, Jiménez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149:315-52.</li>
        <li>Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care 2002;17:93-104.</li>
        <li>Limpus A, Chaboyer W, McDonald E, Thalib L. Mechanical thromboprophylaxis in critically ill patients: a systematic review and metaanálisis Am J Crit Care 2006;15:402-10.</li>
        <li>Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(Suppl 6):381S-453S.</li>
        <li>Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. PROTECT Investigators. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364:1305-14.</li>
    </ol>